BACKGROUND: There is an actual need for novel prognostic biomarkers to improve colorectal cancer (CRC) patient's outcome. OBJECTIVES: To evaluate SOX2 and EpCAM immunohistochemical expression in 40 cases of CRC and premalignant lesions.
METHODS: The immunohistochemical expression was done according to Envision polymer technique on 40 cases of CRC besides twenty specimens of premalignant lesions. Furthermore, their clinicopathological significance was statistically investigated.
RESULTS: High SOX2 immunoexpression was detected in 57.5 % of CRC cases and was significantly associated with tumor size, high tumor grade, LVI, LN involvement, advanced tumor stage, and tumor budding (P=0.04, P